Richard Ernest Gilbert

Title: Richard Ernest Gilbert: Innovator in Therapeutic Compounds

Introduction

Richard Ernest Gilbert is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of therapeutic compounds, holding a total of three patents. His work focuses on innovative medical applications that aim to improve patient outcomes.

Latest Patents

Among his latest patents, one includes therapeutic compounds that are substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity. This patent also covers derivatives, analogs, pharmaceutically acceptable salts, and metabolites, with the specific exclusion of Tranilast. Another significant patent relates to the medical use of a DPP-4 inhibitor, specifically the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, which is intended for patients at risk of or suffering from heart failure with preserved ejection fraction (HFpEF).

Career Highlights

Richard has worked with prominent companies in the pharmaceutical industry, including Fibrotech Therapeutics Pty Ltd and Boehringer Ingelheim International GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas in therapeutic compounds.

Collaborations

Throughout his career, Richard has collaborated with notable professionals in the field, including David Stapleton and Steven Zammit. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Richard Ernest Gilbert is a distinguished inventor whose work in therapeutic compounds has the potential to significantly impact medical treatments. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.